The development of a new diagnostic test ideally follows a sequence of stages which, amongst other aims, evaluate technical performance. This includes an analytical validity study, a diagnostic accuracy study and an interventional clinical utility study. Current approaches to the design and analysis of the diagnostic accuracy study can suffer from prohibitively large sample sizes and interval estimates with undesirable properties. In this paper, we propose a novel Bayesian approach which takes advantage of information available from the analytical validity stage. We utilise assurance to calculate the required sample size based on the target width of a posterior probability interval and can choose to use or disregard the data from the analytical validity study when subsequently inferring measures of test accuracy. Sensitivity analyses are performed to assess the robustness of the proposed sample size to the choice of prior, and prior-data conflict is evaluated by comparing the data to the prior predictive distributions. We illustrate the proposed approach using a motivating real-life application involving a diagnostic test for ventilator associated pneumonia. Finally, we compare the properties of the proposed approach against commonly used alternatives. The results show that by making better use of existing data from earlier studies, the assurance-based approach can not only reduce the required sample size when compared to alternatives, but can also produce more reliable sample sizes for diagnostic accuracy studies.
翻译:开发新的诊断性试验理想地遵循一系列阶段的顺序,这些阶段除其他目的外,还包括评估技术绩效,其中包括分析有效性研究、诊断性准确性研究和干预性临床效用研究。目前设计和分析诊断性精确研究的方法可能受到令人望而却步的抽样规模之大以及不良特性的间隔估计的影响。在本文件中,我们建议采用新的贝叶西亚方法,利用分析有效性阶段的现有信息;我们利用保证,根据外延概率间隔的目标宽度计算所需的样本规模,并可以选择在随后推断测试准确度时使用或无视分析性有效性研究的数据。进行感性分析,以评估拟议样本规模与选择先前和先前数据冲突之间的可靠程度,通过将数据与先前预测性分布进行比较来评估这些方法。我们介绍拟议方法,利用对呼吸器相关的肺炎进行诊断性测试来激发真实生命应用。最后,我们将拟议方法的特性与常用的替代品进行比较。结果显示,如果更好地利用早期研究的现有数据,那么以保证性方法不仅可以降低所需的样本规模,而且可以降低所需的样本规模。